Leerink Partners Reiterates Market Perform Rating on Halozyme Therapeutics (HALO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TD Cowen Reiterates Buy Rating on Halozyme Therapeutics (HALO)
October 3, 2024 2:18 PM EDTTD Cowen analyst Brendan Smith reiterated a Buy rating and $65.00 price target on Halozyme Therapeutics (NASDAQ: HALO).
The analyst commented, "ARGX/HALO expanded their existing ENHANZE collaboration w/ 4 new targets for $7.5M upfront each ($30M total) + tiered mid-single-digit royalties. News adds to Vyvgart Hytrulo... More
Halozyme Therapeutics (HALO) Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE
October 3, 2024 8:01 AM EDTHalozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that argenx has nominated four new targets under its global collaboration and license agreement that provides argenx exclusive access to Halozyme's ENHANZE® drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery. argenx, a global immunology company, now has exclusively licensed ENHANZE® for a total of six targets, including for the neonatal Fc receptor (FcRn) target. VYVGART® Hytrulo, argenx's branded FcRn blocker, is approved by the... More
